200 related articles for article (PubMed ID: 16461786)
1. Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer.
Egloff AM; Weissfeld J; Land SR; Finn OJ
Ann N Y Acad Sci; 2005 Dec; 1062():29-40. PubMed ID: 16461786
[TBL] [Abstract][Full Text] [Related]
2. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease.
Suzuki H; Graziano DF; McKolanis J; Finn OJ
Clin Cancer Res; 2005 Feb; 11(4):1521-6. PubMed ID: 15746055
[TBL] [Abstract][Full Text] [Related]
3. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer.
Cooper WA; Kohonen-Corish MR; McCaughan B; Kennedy C; Sutherland RL; Lee CS
Histopathology; 2009 Jul; 55(1):28-36. PubMed ID: 19614764
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication.
Soria JC; Jang SJ; Khuri FR; Hassan K; Liu D; Hong WK; Mao L
Cancer Res; 2000 Aug; 60(15):4000-4. PubMed ID: 10945597
[TBL] [Abstract][Full Text] [Related]
5. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
6. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.
Sørensen RB; Andersen RS; Svane IM; Engell-Noerregaard L; Hadrup SR; Balslev E; Andersen MH; thor Straten P
Clin Cancer Res; 2009 Mar; 15(5):1543-9. PubMed ID: 19223507
[TBL] [Abstract][Full Text] [Related]
7. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients.
Ersvaer E; Zhang JY; McCormack E; Olsnes A; Anensen N; Tan EM; Gjertsen BT; Bruserud O
Eur J Haematol; 2007 Sep; 79(3):210-25. PubMed ID: 17655707
[TBL] [Abstract][Full Text] [Related]
8. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
Murray PV; Soussi T; O'Brien ME; Smith IE; Brossault S; Norton A; Ashley S; Tavassoli M
Br J Cancer; 2000 Dec; 83(11):1418-24. PubMed ID: 11076647
[TBL] [Abstract][Full Text] [Related]
9. A case-cohort study of an early biomarker of lung cancer in a screening cohort of Yunnan tin miners in China.
Qiao YL; Tockman MS; Li L; Erozan YS; Yao SX; Barrett MJ; Zhou WH; Giffen CA; Luo XC; Taylor PR
Cancer Epidemiol Biomarkers Prev; 1997 Nov; 6(11):893-900. PubMed ID: 9367062
[TBL] [Abstract][Full Text] [Related]
10. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
[TBL] [Abstract][Full Text] [Related]
11. p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate.
Galizia G; Ferraraccio F; Lieto E; Orditura M; Castellano P; Imperatore V; La Manna G; Pinto M; Ciardiello F; La Mura A; De Vita F
J Surg Oncol; 2006 Mar; 93(3):241-52. PubMed ID: 16482605
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY
Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600
[TBL] [Abstract][Full Text] [Related]
13. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression.
Tockman MS; Mulshine JL; Piantadosi S; Erozan YS; Gupta PK; Ruckdeschel JC; Taylor PR; Zhukov T; Zhou WH; Qiao YL; Yao SX
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2237-46. PubMed ID: 9815620
[TBL] [Abstract][Full Text] [Related]
14. Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers.
Shigematsu Y; Hanagiri T; Kuroda K; Baba T; Mizukami M; Ichiki Y; Yasuda M; Takenoyama M; Sugio K; Yasumoto K
Cancer Sci; 2009 Jul; 100(7):1326-34. PubMed ID: 19432887
[TBL] [Abstract][Full Text] [Related]
15. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of cyclin B1 protein expression in colorectal cancer.
Grabsch H; Lickvers K; Hansen O; Takeno S; Willers R; Stock W; Gabbert HE; Mueller W
Am J Clin Pathol; 2004 Oct; 122(4):511-6. PubMed ID: 15487447
[TBL] [Abstract][Full Text] [Related]
17. VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer.
Dalaveris E; Kerenidi T; Katsabeki-Katsafli A; Kiropoulos T; Tanou K; Gourgoulianis KI; Kostikas K
Lung Cancer; 2009 May; 64(2):219-25. PubMed ID: 18845357
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
19. Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters.
Vural B; Chen LC; Saip P; Chen YT; Ustuner Z; Gonen M; Simpson AJ; Old LJ; Ozbek U; Gure AO
Cancer; 2005 Jun; 103(12):2575-83. PubMed ID: 15880380
[TBL] [Abstract][Full Text] [Related]
20. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R
Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
